Triazole resistance prevalence in Aspergillus fumigatus in Mexico and Peru

• Autores: Resendiz-Sharpe, Agustin, Bustamante, Beatriz, Merckx, R., Jacobs, J., Maertens,J., Verweij,P., Lagrou, K.
• Formato: objeto de conferencia
• Fecha de Publicación: 2019
• Institución: Universidad Peruana Cayetano Heredia
• Repositorio: UPCH-Institucional
• Lenguaje: inglés
• OAI Identifier: oai:repositorio.upch.edu.pe:20.500.12866/12741
• Enlace del recurso: https://hdl.handle.net/20.500.12866/12741
• Nivel de acceso: acceso abierto
• Materia: Triazole; Aspergillus fumigatus; Mexico; Peru

Introduction: Triazole-antifungal treatment, the recommended first-line therapy for aspergillosis, is threatened as triazole-resistance reports in Aspergillus fumigatus increase worldwide. Infection by resistant isolates not only occurs during prolonged triazole-treatments but also by inhalation of triazole-resistant spores from the environment. Modifications to the recommended initial triazole antifungal therapy have been proposed by an international expert consensus in centers with >10% environmental-resistance. However, triazole-resistance prevalence is not known in most countries as susceptibility testing is not routinely performed.Objective: To determine the prevalence of environmental triazole-resistant A. fumigatus in two Latin American countries, Mexico and Peru.Methodology: Environmental sampling. Triazole-resistance screening. Triazole-resistance confirmation.Results: A total of 304 soil samples were analyzed. Screening of environmental triazole-resistant A. fumigatus in Mexico and Peru.Conclusions: For the first time, triazole-resistant A. fumigatus was detected in soil samples in Mexico and Peru with a resistance prevalence of 6.9% and 9.8% respectively among A. fumigatus positive samples. Our findings emphasize the need to perform resistance screening or surveillance in clinical settings in these countries.